Ashwin Gollerkeri

Ashwin Gollerkeri

UNVERIFIED PROFILE

Are you Ashwin Gollerkeri?   Register this Author

Register author
Ashwin Gollerkeri

Ashwin Gollerkeri

Publications by authors named "Ashwin Gollerkeri"

Are you Ashwin Gollerkeri?   Register this Author

10Publications

222Reads

29Profile Views

Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.

N Engl J Med 2019 10 30;381(17):1632-1643. Epub 2019 Sep 30.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.K., V.M.); West Cancer Center and Research Institute, OneOncology, Germantown, TN (A. Grothey); Memorial Sloan Kettering Cancer Center, New York (R.Y., A.K.); University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium (E.V.C., J. Dekervel); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (J. Desai, C.G.); National Cancer Center Hospital East, Kashiwa, Japan (T.Y.); Hammersmith Hospital, Division of Cancer, Imperial College London (H.W.), and the Sarah Cannon Research Institute and University College London Cancer Institute (H.-T.A.), London, and the Christie NHS Foundation Trust/National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.B.) - all in the United Kingdom; the University of Campania Luigi Vanvitelli, Naples (F.C.), and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua (F.L., S.L.) - both in Italy; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (Y.S.H., T.-W.K.); the Netherlands Cancer Institute, Amsterdam (N.S., J.H.M.S.); Oslo University Hospital, Oslo (T.K.G.); Hospital Gregorio Marañón, Madrid (P.G.-A., A.C.F.), and Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, UVic, IOB-Quiron, Barcelona (E.E., J.T.) - both in Spain; Odense University Hospital, Odense, Denmark (P.P., L.S.T.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (S.O.); and Array BioPharma, Boulder, CO (A. Gollerkeri, C.K., K.M., M.P., J.C.-B., L.A., V.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908075DOI Listing
October 2019

Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies.

Clin Cancer Res 2005 May;11(9):3335-41

Experimental Therapeutics and Phase I Programs, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9497, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/11/9/3335.full
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-04-1494DOI Listing
May 2005

Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.

Clin Cancer Res 2003 Nov;9(14):5187-94

Oncology Division, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

View Article

Download full-text PDF

Source
November 2003